An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in alzheimer’s disease

Tacrine 970-6 Study Group

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

We studied the effects of 40 and 80 mg/day of tacrine on patients with probable Alzheimer’s disease (AD) in an 8-week, randomized, double-blind, placebo-controlled crossover trial with an enriched-population design. In the initial dose titration phases an intent-to-treat analysis showed significantly more improvement with 80 mg/day of tacrine than placebo. In the subsequent crossover trial that included only ‘responders’, no significant improvement was observed with tacrine, whether or not it was given with lecithin. We found that individualized dose titration and enrichment strategies were not helpful and had the effect of reducing the power of the study. In the dose titration phase of this study we found that more impaired subjects were as likely to improve as those who were less impaired, suggesting that tacrine should be further investigated in more severely demented AD patients.

Original languageEnglish (US)
Pages (from-to)260-266
Number of pages7
JournalDementia and geriatric cognitive disorders
Volume7
Issue number5
DOIs
StatePublished - Jan 1 1996

Keywords

  • Alzheimer’s disease
  • Cholinesterase inhibitors
  • Lecithin
  • Randomized clinical trials
  • Tacrine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Cognitive Neuroscience
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in alzheimer’s disease'. Together they form a unique fingerprint.

  • Cite this